Provided by Tiger Fintech (Singapore) Pte. Ltd.

Orchestra BioMed

3.09
-0.0800-2.52%
Post-market: 3.220.1300+4.21%17:16 EDT
Volume:85.84K
Turnover:267.02K
Market Cap:118.39M
PE:-1.74
High:3.22
Open:3.22
Low:3.04
Close:3.17
Loading ...

Orchestra BioMed Highlights Strategic Initiatives and Innovations

TIPRANKS
·
03 Mar

Orchestra BioMed Updates Executive Compensation Policies

TIPRANKS
·
26 Feb

Orchestra names Vivek Reddy as chairman of BACKBEAT study steering committee

TIPRANKS
·
18 Feb

Orchestra Biomed Appoints Vivek Reddy, M.d. as Executive Chairman of the Backbeat Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

THOMSON REUTERS
·
18 Feb

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

GlobeNewswire
·
18 Feb

Orchestra BioMed Says AVIM Therapy Improves Echo Markers of Diastolic Dysfunction

MT Newswires Live
·
13 Feb

Orchestra BioMed announces data on atrioventricular interval modulation therapy

TIPRANKS
·
12 Feb

Orchestra Biomed Announces Data Demonstrating Favorable Impact of Avim Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, Will Be Presented as Late-Breaking Science at the Tht 2025 Conference

THOMSON REUTERS
·
12 Feb

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

GlobeNewswire
·
12 Feb

Orchestra BioMed Appoints New Director Amid Board Changes

TIPRANKS
·
05 Feb

Orchestra BioMed announces appointment of Cleary to board of directors

TIPRANKS
·
05 Feb

Orchestra Biomed Announces Appointment of Former Medtronic Svp of Corporate Development Christopher Cleary to Board of Directors

THOMSON REUTERS
·
05 Feb

Press Release: Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Dow Jones
·
05 Feb